News

Exciting Advances in Gene Therapy Presented by AskBio

Exciting Advances in Gene Therapy Presented by AskBio

Breakthrough Presentations at ESGCT Annual Meeting

Asklepios BioPharmaceutical, Inc. (AskBio) is set to showcase its advancements in gene therapy at the upcoming European Society of Gene and Cell Therapy (ESGCT) 31st Annual Meeting. This event marks a significant opportunity for AskBio to share its progress in both clinical and pre-clinical settings concerning adeno-associated virus (AAV) therapies. The meeting will take place in Rome, bringing together experts and innovators in the field.

Highlights of Presentations

AskBio will feature an impressive lineup of 11 presentations, consisting of two oral sessions and nine poster sessions. These presentations underscore the company’s ongoing commitment to advancing its pioneering research and development initiatives. Notably, this year’s presentations tie into recent milestones in AskBio's clinical programs, such as the commencement of recruitment for the Phase 2 GenePHIT trial for AB-1002, an investigational gene therapy targeting congestive heart failure.

Oral Presentations

The oral presentations are designed to present new strategies in gene therapy, particularly the focus on treating central nervous system disorders. Noteworthy sessions will include:

  • In Vivo Gene Therapy Strategies – Focus on CNS (EDU07) - This session will delve into innovative approaches for treating diseases that affect the central nervous system.
  • Clinical Progress for AB-1005 (AAV2GDNF) - This presentation will provide insights into the developments for treating Parkinson’s disease, demonstrating AskBio's commitment to addressing severe neurological challenges.

Poster Sessions

In addition to oral presentations, AskBio will showcase a variety of research posters that include:

  • Evaluation of Mutant Huntingtin Knockdown - This research investigates the effects of AAV-miHTT constructs in pre-clinical models of Huntington’s disease.
  • Enhancing AAV Vector Manufacturing - This session focuses on advanced methods to optimize the production of AAV vectors, crucial for effective gene therapy.
  • Characterization of rAAV Products - Presenters will discuss methods for improving the characterization of AAV products using high-throughput screening technologies.

Commitment to Innovation

Under the leadership of CEO Gustavo Pesquin, AskBio continues to reinforce its dedication to research and the development of next-generation therapies. The company employs a robust gene therapy platform, which includes its proprietary Pro10™ production process. This unique process enables the production of effective gene therapies while paving the way for advancements that have the potential to transform patient care for conditions like Huntington’s disease, cardiac dysfunction, and other severe conditions.

About AskBio

AskBio is wholly owned by Bayer AG and serves as a fully integrated gene therapy company. With various clinical programs in place aimed at addressing significant diseases across neuromuscular and metabolic conditions, the commitment to innovation and effective patient outcomes is at the forefront of its mission.

Frequently Asked Questions

What is the ESGCT Annual Meeting?

The ESGCT Annual Meeting is a significant event where scientists and industry leaders gather to share advancements and research in gene and cell therapy.

How many presentations will AskBio deliver?

AskBio will deliver a total of 11 presentations, including both oral and poster formats at the upcoming ESGCT Annual Meeting.

What are the main focus areas of AskBio's research?

AskBio focuses on developing gene therapies for neuromuscular, central nervous system, cardiovascular, and metabolic conditions, including significant diseases like Parkinson’s Disease and congestive heart failure.

Who is leading AskBio?

Gustavo Pesquin serves as the Chief Executive Officer of AskBio and leads the organization in its mission to develop cutting-edge therapies.

What is Pro10™?

Pro10™ is AskBio's proprietary cell line manufacturing process designed to optimize the production of gene therapies, significantly enhancing the efficiency and effectiveness of therapeutic development.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Small Business Insurance Is a Costly Blind Spot Today

Updated Category News Views 131

A busted pipe, a fender-bender, or one bad fall can turn a promising little company into a very expensive regret. That is the plain-English value in insurance expert Michael Oehrke's overview for HelloNation: small-business insurance is not glamorous, it is not growth marketing, and it is often ignored until the owner is staring at a bill that can chew through years of...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 199

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 57

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
Carbonization Furnaces Turn Waste Rules Into Demand

Updated Category News Views 112

Smoke has become an expensive habit for farmers, mills, and municipalities. That is the real commercial backdrop for carbonization furnaces, not some glossy green-tech slogan. MarketsandMarkets estimates this small global equipment market at $310 million in 2026 and projects $510 million by 2031, a 10.2% compound annual growth rate. For a capital-equipment niche, that is...

Continue Reading
UnitedHealth’s CMS Audit Shock Puts Disclosures Under Lens

Updated Category News Views 98

Medicare Advantage's audit bill just landed with a nasty thud. UnitedHealth Group shares fell more than 10% on November 18 after the Centers for Medicare & Medicaid Services proposed new anti-fraud, audit, and repayment rules for the program. For holders of NYSE:UNH, this was not some sleepy policy memo buried in a federal filing cabinet. It was a hard reminder that...

Continue Reading
Bella Rio's Proposed Preferred B Share Giveaway Plan

Updated Category News Views 46

A founder handing over two million of his own common shares is the sort of detail that makes investors stop stirring their coffee. Bella Rio Consulting, the company behind ROCK'N Vodka and Bella Rio Bourbon, says co-founder and Vice President Andy Roiniotis proposes to contribute 2,000,000 personally held Common shares for reclassification into Preferred Series B shares....

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 84

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 111

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 91

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Geothermal AI Nodes Take Aim at Stranded Well Power

Updated Category News Views 175

Millions of idle wells are sitting under America like unwanted basement clutter, and GEIOS GEOFLEX thinks some can become small, self-contained AI power plants. That is the provocative idea behind its Dark Token Factory partnership with Aiden Digital Labs: bolt an autonomous compute module onto an abandoned or non-producing oil and gas well, pull geothermal heat from...

Continue Reading

Top 5 Most Recently Viewed Articles

Canada Nickel Secures EDC Interest for $500 Million Financing

Updated Category News Views 137

Canada Nickel's Significant Financing Achievement Canada Nickel Company Inc. is excited to share a major milestone in its efforts to secure financing for the Crawford Nickel Sulphide Project. The company has received a Letter of Interest (LOI) from Export Development Canada (EDC), indicating its intention to offer up to US$500 million in long-term debt financing for the...

Continue Reading
BlackRock Expands Offerings with New ETF Share Class Approval

Updated Category News Views 202

BlackRock Pursues SEC Approval for ETF Share Classes BlackRock Inc (NYSE: BLK) is making headlines as it has formally applied to the U.S. Securities and Exchange Commission (SEC) for a ruling that would allow the establishment of exchange-traded fund (ETF) share classes linked to its existing mutual funds. This significant move positions BlackRock as the largest firm...

Continue Reading
Profusa Unveils Innovative AI Portal for Continuous Biochemistry Monitoring

Updated Category News Views 133

Profusa Introduces AI-Powered Insight Portal for Biomarker Monitoring Profusa, a pioneering company in digital health technology, is transforming how healthcare providers monitor patient biochemistry through an innovative AI-driven insight portal. This advanced portal will enhance continuous biomarker tracking, utilizing cutting-edge technology to provide clinical...

Continue Reading
Investigation Launch for Pliant Therapeutics Investors: What to Know

Updated Category News Views 192

Investigation of Pliant Therapeutics, Inc. Pliant Therapeutics, Inc. (NASDAQ: PLRX) is currently under scrutiny as investors seek clarity on potential securities law violations. This investigation presents an opportunity for shareholders who believe they have been misled regarding their investments. Shareholders are encouraged to come forward to ensure their rights are...

Continue Reading
Fish Window Cleaning's New Headquarters: A Step Forward in Growth

Updated Category News Views 2161

Fish Window Cleaning Unveils New Corporate Headquarters Fish Window Cleaning Services is excited to announce the grand opening of its brand-new corporate headquarters, a facility that signifies an important milestone in its growth and operational capabilities. Located at 217 Chesterfield Towne Centre, this expansive 12,500-square-foot space is intended to serve as the...

Continue Reading